Clinical trials: Bladder Cancer Stage
Breast Cancer, Colon Cancer
Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
Background: Drugs given to treat cancer (chemotherapy) can weaken the human immune system. But it can also become weaker because of aging.
- Conditions
- Breast Cancer, Colon Cancer, Bladder Cancer
- Trial name
- NCT01339000
- Testing
- Glycosylated Recombinant Human Interleukin-7, Diphtheria/Tetanus Vaccine, Polio Vaccine
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Urothelial Carcinoma, Urothelial Carcinoma Bladder
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in combination with the investigational agent sitravatinib in patients with advanced or metastatic urothelial carcinoma.
- Conditions
- Urothelial Carcinoma, Urothelial Carcinoma Bladder, Urothelial Carcinoma Ureter, Urothelial Carcinoma of the Renal Pelvis and Ureter
- Trial name
- NCT03606174
- Testing
- Sitravatinib, Nivolumab, Pembrolizumab
- Where
- 36 sites in United States
- Volunteers
- 260 people
- Sponsor
- Mirati Therapeutics Inc.
Muscle Invasive Bladder Cancer, High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of…
- Trial name
- NCT01031420
- Testing
- single arm dose dense MVAC
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fox Chase Cancer Center
Biliary Carcinoma, Gall Bladder Carcinoma
Copanlisib (BAY 80-6946) in Combination With Gemcitabine and Cisplatin in Advanced Cholangiocarcinoma
The purpose of this study is to see if an experimental drug, called copanlisib is effective and safe in treating adult participants with cholangiocarcinoma, when used in combination with gemcitabine and cisplatin.
- Conditions
- Biliary Carcinoma, Gall Bladder Carcinoma, Cholangiocarcinoma, Gastrointestinal Tumor
- Trial name
- NCT02631590
- Testing
- Cisplatin, Gemcitabine, Copanlisib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Advanced Cancer, Metastatic Cancer
A Study of LY3076226 in Participants With Advanced or Metastatic Cancer
The main purpose of this study is to evaluate the safety of the study drug known as LY3076226 in participants with advanced or metastatic cancer.
- Trial name
- NCT02529553
- Testing
- LY3076226
- Where
- 4 sites in United States, Canada
- Volunteers
- 25 people
- Sponsor
- Eli Lilly and Company
Bladder Cancer
Mitomycin C Versus Bacillus Calmette-Guerin in the Intravesical Treatment of Non-Muscle-Invasive Bladder Cancer Patients
The purpose of this study is to compare the bladder cancer treatments, Mitomycin C (MMC) and Bacillus Calmette Guerin (BCG), to find out which is better.
- Trial name
- NCT00974818
- Testing
- Mitomycin C (MMC), Bacillus Calmette-Guerin (BCG)
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Neoplasms, Solid Tumors
My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors
This multicenter, non-randomized, open-label study will evaluate the efficacy and safety of six treatment regimens in participants with advanced solid tumors for whom therapies that will convey clinical benefit are not available…
- Conditions
- Neoplasms, Solid Tumors, Biliary Cancer, Salivary Cancer
- Trial name
- NCT02091141
- Testing
- Trastuzumab, Pertuzumab, Erlotinib
- Where
- 60 sites in United States
- Volunteers
- 673 people
- Sponsor
- Genentech, Inc.
Bladder Cancer
Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer
The purpose of this study is to test the safety of avelumab and Bacille Calmette-Guerin (BCG) and see what effects (good and bad) that this combination treatment has on subjects with recurrent bladder cancer.
- Trial name
- OU-SCC-ABC (NCT03892642)
- Testing
- Avelumab, BCG
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- University of Oklahoma
Bladder Cancer
MK-3475/BCG in High Risk Superficial Bladder Cancer
This is a single center Phase I safety and efficacy study of MK-3475 therapy used in combination with bladder infused BCG treatment for patients, 18 years or older, with high risk superficial bladder cancer (cancer not yet…
- Trial name
- MARC (NCT02324582)
- Testing
- Intravenous MK-3475/ Intravesical BCG
- Where
- 3 sites in United States
- Volunteers
- 18 people
- Sponsor
- Southern Illinois University
Muscle Invasive Bladder Cancer
BLASST-1 (Bladder Cancer Signal Seeking Trial): Nivolumab, Gemcitabine, and Cisplatin in Treatment of Muscle Invasive Bladder Cancer (MIBC) Undergoing Cystectomy
This is a multi-center Phase II study to determine the safety and efficacy of nivolumab when given in combination with cisplatin and gemcitabine as neoadjuvant treatment in patients with muscle-invasive bladder cancer (MIBC)…
- Trial name
- NCT03294304
- Testing
- Nivolumab, Cisplatin, Gemcitabine
- Where
- 3 sites in United States
- Volunteers
- 43 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Bladder Cancer
Gemcitabine and Pazopanib in Chemotherapy Naïve Patients With Advanced/Metastatic Urothelial Carcinoma Ineligible for Cisplatin-based Chemotherapy
Gemcitabine and Cisplatin are standard chemotherapy drugs used to treat advanced urothelial cancer. There is no standard chemotherapy for patients who cannot receive Cisplatin.
- Trial name
- NCT01622660
- Testing
- Gemcitabine, Pazopanib
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Bladder Cancer
Checkpoint Inhibitor and Radiation Therapy in Bulky, Node-Positive Bladder Cancer
Clinically node positive (cN+) bladder cancer carries a poor prognosis, especially in patients who are unable to receive or fail to respond to neoadjuvant chemotherapy.
- Trial name
- CIRTiN-BC (NCT04779489)
- Testing
- personalized ultrafractionated stereotactic ablative radiotherapy
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- University of Texas Southwestern Medical Center
Transitional Cell Carcinoma
Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial Cancer
This phase II trial studies how well paclitaxel and pembrolizumab works in treating patients with urothelial cancer that has not responded to previous treatment and has spread to other places in the body.
- Trial name
- NCT02581982
- Testing
- Laboratory Biomarker Analysis, Paclitaxel, Pembrolizumab
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
Various Advanced Cancer
A Study of Nivolumab in Participants With Metastatic or Unresectable Bladder Cancer
The purpose the study is to measure the effect of nivolumab (BMS-936558) in reducing tumor size in subjects with metastatic or unresectable bladder cancer.
- Trial name
- NCT02387996
- Testing
- Nivolumab
- Where
- 67 sites in United States, Australia and 9 more
- Volunteers
- 270 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms
Dose Escalation Pan-FGFR (Fibroblast Growth Factor Receptor) Inhibitor (Rogaratinib)
This was the first study where BAY1163877 was given to humans. Impact of the study was to evaluate if patients with advanced solid cancers show advanced clinical benefit under the treatment with the pan FGFR inhibitor.
- Trial name
- NCT01976741
- Testing
- Rogaratinib (BAY1163877) oral solution, Rogaratinib (BAY1163877) oral tablet, Rogaratinib (BAY1163877) 800 mg BID
- Where
- 29 sites in United States, France and 5 more
- Volunteers
- 168 people
- Sponsor
- Bayer
Bladder Cancer
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma
This is a Phase II, nonrandomized multicenter study designed to evaluate time to progression and response proportion of patients with advanced or metastatic transitional cell carcinoma of bladder receiving 6 cycles of…
- Trial name
- NCT00461851
- Testing
- Gemcitabine, Carboplatin, Sorafenib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Yale University
Urothelial Carcinoma, Bladder Cancer
Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects
This is a pre-surgical study involving subjects with muscle invasive bladder cancer, or urothelial cancer, who are candidates for neoadjuvant therapy.
- Trial name
- NCT02365766
- Testing
- Pembrolizumab, Gemcitabine, Cisplatin
- Where
- 9 sites in United States
- Volunteers
- 83 people
- Sponsor
- Jason R. Brown
Bladder Cancer
Radiation Therapy and Chemotherapy in Treating Patients With Stage I Bladder Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal…
- Trial name
- NCT00981656
- Testing
- cisplatin, 5-fluorouracil, Mitomycin
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Radiation Therapy Oncology Group
Urothelial Carcinoma
Phase 1b/2 Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab in Urothelial Carcinoma
FORT-2 is designed to evaluate safety, efficacy, RP2D and PK of rogaratinib in combination with atezolizumab in patients with untreated FGFR-positive urothelial carcinoma.
- Trial name
- FORT-2 (NCT03473756)
- Testing
- Rogaratinib (BAY1163877), Atezolizumab
- Where
- 30 sites in United States, Austria and 6 more
- Volunteers
- 37 people
- Sponsor
- Bayer
Bladder Cancer
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00526656
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center